Antidepressant-induced increase in high-affinity rolipram binding sites in rat brain: Dependence on noradrenergic and serotonergic function

Journal of Pharmacology and Experimental Therapeutics

Volumn 307, Issue 1, 2003, Pages 246-253

  Zhao, Yu ^a   Zhang, Han Ting ^a   O'Donnell, James M ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,7 DIHYDROXYTRYPTAMINE; ANTIDEPRESSANT AGENT; DESIPRAMINE; FLUOXETINE; NORADRENALIN; OXIDOPAMINE; PHOSPHODIESTERASE IV; PICLAMILAST; ROLIPRAM; SEROTONIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING SITE; BRAIN CORTEX; CONTROLLED STUDY; CYTOSOL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BINDING; HIGH AFFINITY ROLIPRAM BINDING SITE; HIPPOCAMPUS; LOW AFFINITY ROLIPRAM BINDING SITE; MALE; NONHUMAN; NORADRENERGIC NERVE; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR UPREGULATION; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; BINDING SITES; BRAIN; CELL MEMBRANE; CEREBRAL CORTEX; DESIPRAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HIPPOCAMPUS; MALE; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ADRENERGIC; RECEPTORS, SEROTONIN; ROLIPRAM; TIME FACTORS; TRITIUM;

EID: 0141742426     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.053215     Document Type: Article

References (40)

1. Barnette MS, Grous M, Cieslinski LB, Burman M, Christensen SB, and Torphy TJ (1995) Inhibitors of phosphodiesterase IV (PDE IV) increase acid secretion in rabbit isolated gastric glands: correlation between function and interaction with a high-affinity rolipram binding site. J Pharmacol Exp Ther 273:1396-1402.
2. Bobon D, Breulet M, Gerard-Vandenhove MA, Guiot-Goffioul F, Plomteux G, Sastrey-Hernandez M, Schratzer M, Troisfontaines B, von Frenckell R, and Wachtel H (1988) Is phosphodiesterase inhibition a new mechanism of antidepressant action? A double blind double-dummy study between rolipram and desipramine in hospitalized major and/or endogenous depressives. Eur Arch Psychiatry Neurol Sci 238:2-6.
3. Breese GR and Traylor TD (1971) Depletion ofbrain noradrenaline and dopamine by 6-hydroxydopamine. Br J Pharmacol 42:88-99.
4. Bremner JD, Randall P, Scott TM, Bronen RA, Seibyl JP, Southwick SM, Delaney RC, McCarthy G, Charney DS, and Innis RB (1995) MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. Am J Psychiatry 152:973-981.
5. Dalgarno DC, Botfield MC, and Rickles RJ (1997) SH3 domains and drug design: ligands, structure and biological function. Biopolymers 43:383-400.
6. 3H]-imipramine. J Pharmacol Exp Ther 242:364-371.
7. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, and Raichle ME (1997) Subgenual prefrontal cortex abnormalities in mood disorders. Nature (Lond) 386:824-827.
8. Duman RS, Heninger GR, and Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54:597-606.
9. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J Med Chem 39:120-125.
10. Hoffmann R, Wilkinson IR, McCallum JF, Engels P, and Houslay MD (1998) cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model. Biochem J 333:139-149.
11. Huston E, Beard M, McCallum F, Pyne NJ, Vandenabeele P, Scotland G, and Houslay MD (2000) The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution. J Biol Chem 275:28063-28074.
12. Huston E, Pooley L, Julien P, Scotland G, McPhee I, Sullivan M, Bolger G, and Houslay MD (1996) The human cyclic AMP-specific phosphodiesterase PDE-46 (HSPDE4A4B) expressed in transfected COS7 cells occurs as both particulate and cytosolic species that exhibit distinct kinetics of inhibition by the antidepressant rolipram. J Biol Chem 271:31334-31344.
13. Jacobitz S, McLaughlin MM, Livi GP, Burman M, and Torphy TJ (1996) Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. Mol Pharmacol 50:891-899.
14. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, et al. (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39:6449-6458.
15. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, and Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40:10179-10186.
16. McPhee I, Yarwood SJ, Scotland G, Huston E, Beard MB, Ross AH, Houslay ES, and Houslay MD (1999) Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition. J Biol Chem 274:11796-11810.
17. Miller HL, Delgado PL, Salomon RM, Berman R, Krystal JH, Heninger GR, and Charney DS (1996) Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression. Arch Gen Psychiatry 53:117-128.
18. Mongeau R, Blier P, and de Montigny C (1997) The serotonergic and noradrenergic systems of the hippocampus: their interactions and the effects of antidepressant treatments. Brain Res Rev 23:145-195.
19. Nestler EJ, Terwilliger RZ, and Duman RS (1989) Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem 53:1644-1647.
20. Nibuya M, Nestler EJ, and Duman RS (1996) Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci 16:2365-2372.
21. O'Donnell JM (1993) Antidepressant-like effects of rolipram and other inhibitors of cyclic adenosine monophosphate phosphodiesterase on behavior maintained by differential reinforcement oflow response rate. J Pharmacol Exp Ther 264:1168-1178.
22. O'Donnell JM, Frith S, and Wilkins J (1994) Involvement of beta-1 and beta-2 adrenergic receptors in the antidepressant-like effects of centrally administered isoproterenol. J Pharmacol Exp Ther 271:246-254.
23. O'Donnell JM, Wolfe BB, and Frazer A (1984) Agonist interactions with beta adrenergic receptors in rat brain. J Pharmacol Exp Ther 228:640-647.
24. Ozawa H, Rasenick MM, Takahata N, and Saito T (1991) The effects of electroconvulsive shock on receptor-G protein-adenylate cyclase coupling. Jpn J Psychiatry Neurol 45:137-138.
25. Saccomano N, Vinick FJ, Koe BK, Nielsen JA, Whalen WM, Meltz M, Phillips D, Thadieo PF, Jung S, Chapin DS, et al. (1991) Calcium-independent phosphodiesterase inhibitors as putative antidepressants: [3-(bicycloalkyloxy)-4-methoxyphenyl]-2-imidazolidinones. J Med Chem 34:291-298.
26. Schmiechen R, Schneider HH, and Wachtel H (1990) Close correlation between behavioural response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacol Ser (Berl) 102:17-20.
27. Schneider HH, Schmiechen R, Brezinski M, and Seidler J (1986) Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol 127:105-115.
28. Sette C and Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271:16526-16534.
29. Shah PJ, Ebmeier KP, Glabus MF, and Goodwin GM (1998) Cortical grey matter reductions associated with treatment-resistant chronic unipolar depression. Controlled magnetic resonance imaging study. Br J Psychiatry 172:527-532.
30. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, and Klenk DC (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:461-480.
31. Souness JE, Maslen C, and Scott LC (1992) Effects of solubilization and vanadate/glutathione complex on inhibitor potencies against eosinophil cyclic AMP-specific phosphodiesterase. FEBS Lett 302:181-184.
32. Suda S, Nibuya M, Ishiguro T, and Suda H (1998) Transcriptional and translational regulation of phosphodiesterase type IV isozymes in rat brain by electroconvulsive seizure and antidepressant drug treatment. J Neurochem 71:1554-1563.
33. Takahashi M, Terwilliger R, Lane C, Mezes PS, Conti M, and Duman RS (1999) Chronic antidepressant administration increases the expression of cAMP-specific phosphodiesterase 4A and 4B isoforms. J Neurosci 19:610-618.
34. 3H]Nisoxetine: a radioligand for quantitation of norepinephrine uptake sites by autoradiography or by homogenate binding. J Pharmacol Exp Ther 260:427-436.
35. Yarwood SJ, Steele MR, Scotland G, Houslay MD, and Bolger GB (1999) The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform. J Biol Chem 274:14909-14917.
36. Ye Y, Conti M, Houslay MD, Farooqui SM, Chen M, and O'Donnell JM (1997) Noradrenergic activity differentially regulates the expression of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase (PDE4) in rat brain. J Neurochem 69:2397-2404.
37. Ye Y, Jackson K, and O'Donnell JM (2000) Effects of repeated antidepressant treatment on type 4A phosphodiesterase (PDE4A) in rat brain. J Neurochem 74:1257-1262.
38. Ye Y and O'Donnell JM (1996) Diminished noradrenergic stimulation reduces the activity of rolipram-sensitive, high-affinity cyclic AMP phosphodiesterase in rat cerebral cortex. J Neurochem 66:1894-1902.
39. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, and O'Donnell JM (2002) Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology 27:587-595.
40. 3H]-rolipram. J Pharmacol Exp Ther 305:565-572.